GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Faes Farma SA (XMAD:FAE) » Definitions » Net-Net Working Capital

Faes Farma (XMAD:FAE) Net-Net Working Capital : €0.29 (As of Jun. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Faes Farma Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Faes Farma's Net-Net Working Capital for the quarter that ended in Jun. 2023 was €0.29.

The industry rank for Faes Farma's Net-Net Working Capital or its related term are showing as below:

XMAD:FAE's Price-to-Net-Net-Working-Capital is ranked worse than
74.08% of 409 companies
in the Drug Manufacturers industry
Industry Median: 6.93 vs XMAD:FAE: 15.08

Faes Farma Net-Net Working Capital Historical Data

The historical data trend for Faes Farma's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Faes Farma Net-Net Working Capital Chart

Faes Farma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.27 0.35 0.31 0.29 0.25

Faes Farma Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.29 - 0.29 0.25

Competitive Comparison of Faes Farma's Net-Net Working Capital

For the Drug Manufacturers - Specialty & Generic subindustry, Faes Farma's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Faes Farma's Price-to-Net-Net-Working-Capital Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Faes Farma's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Faes Farma's Price-to-Net-Net-Working-Capital falls into.



Faes Farma Net-Net Working Capital Calculation

Faes Farma's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net-Net Working Capital(A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(47.751+0.75 * 104.092+0.5 * 128.656-112.68
-0-0.994)/311.249
=0.25

Faes Farma's Net-Net Working Capital (NNWC) per share for the quarter that ended in Jun. 2023 is calculated as

Net-Net Working Capital(Q: Jun. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(46.515+0.75 * 120.557+0.5 * 131.944-110.663
-0-1.185)/314.021
=0.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Faes Farma  (XMAD:FAE) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Faes Farma Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Faes Farma's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Faes Farma (XMAD:FAE) Business Description

Traded in Other Exchanges
Address
Maximo Aguirre, 14, Leioa, Vizcaya, ESP, 48940
Faes Farma SA is a pharmaceutical company that specializes in the research, production, distribution, and sale of prescription and generic drugs, over-the-counter medicines, food supplements and personal care treatments, as well as raw materials for the pharmaceutical use. The company develops new drugs for the treatment of allergy, venous insufficiency, and irritable bowel syndrome. It also provides animal nutrition products. Faes Farma exports its products to more than 60 countries and has operations in Spain, Portugal, Chile, and Mexico, among others.

Faes Farma (XMAD:FAE) Headlines

No Headlines